Please wait while we retrieve your external webpage

SOLO-1 Phase III Trial Demonstrates Lynparza Maintenance Therapy Cut Risk Of Disease Progression Or Death By 70% In Patients With Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer

Leave a Reply